Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells

Paquette, Ronald; Hsu, Nancy; Kiertscher, Sylvia M.; Park, Alice N.; Tran, Lawrence; Roth, Michael D.; Glaspy, John A.

doi:10.1002/jlb.64.3.358

Cited by 250 publications

(185 citation statements)

References 62 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Normal PBMCs cultured under these conditions have a similar morphology and immunopheno- type. 19 The CML DCs cultured in either IFN-␣/GM-CSF or IL-4/GM-CSF expressed similar levels of DC antigens, except the class I and II HLA proteins which were significantly more abundant on DCs grown in IFN-␣/GM-CSF. Normal DCs prepared with IFN-␣/GM-CSF also express higher levels of HLA proteins than those grown in IL-4/GM-CSF.…”

Section: Discussionmentioning

confidence: 90%

“…[16][17][18] We previously reported that peripheral blood monocytes cultured in media containing IFN-␣ and GM-CSF differentiated into DCs. 19 Because IFN-␣ is used as immunotherapy for various malignancies, including CML, it is possible that the therapeutic efficacy of this agent may be partially due to its affect on DC development. Therefore, the ability of IFN-␣ to differentiate CML mononuclear cells into DCs was evaluated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo

Paquette¹,

Hsu²,

Said³

et al. 2002

Leukemia

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo

Paquette¹,

Hsu²,

Said³

et al. 2002

Leukemia

View full text Add to dashboard Cite

“…In addition to their cytotoxic effects on selected tumor cells, 55 type I IFNs are known to have broader effects on the immune system by influencing the function and phenotype of dendritic cells (DCs) and T cells. [56][57][58] The fact that EGFR-MSC did not suppress allogeneic MLR responses may be a favorable characteristic for their application in immunotherapy approaches.…”

Section: Discussionmentioning

confidence: 99%

Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors

et al. 2005

View full text Add to dashboard Cite

We have created a novel cellular vehicle for gene therapy of malignant gliomas by transfection of murine bone marrow stroma cells (MSCs) with a cDNA encoding epidermal growth factor receptor (EGFR). These cells (EGFR-MSCs) demonstrate enhanced migratory responses toward glioma-conditioned media in comparison to primary MSCs in vitro. Enhanced migration of EGFR-MSC was at least partially dependent on EGF-EGFR, PI3-, MAP kinase kinase, and MAP kinases, protein kinase C, and actin polymerization. Unlike primary MSCs, EGFR-MSCs were resistant to FasL-mediated cytotoxicity and were capable of stimulating allogeneic mixed lymphocyte reaction, suggesting EGFR-MSCs possess suitable characteristics as vehicles for brain tumor immuno-gene therapy. Following injection at various sites, including the contralateral hemisphere in the brain of syngeneic mice, EGFR-MSCs were able to migrate toward GL261 gliomas or B16 melanoma in vivo. Finally, intratumoral injection with EGFR-MSC adenovirally engineered to secrete interferon-a to intracranial GL261 resulted in significantly prolonged survival in comparison to controls. These data indicate that EGFR-MSCs may serve as attractive vehicles for infiltrating brain malignancies such as malignant gliomas.

show abstract

“…Recently, type I IFN has been shown to promote the in vivo proliferation and long-term survival of antigen-specific CD8 + T cells in mouse models, 37,38 and to favor a Th-1 type of immune response 39,40 as well as the differentiation and functional activation of dendritic cells in human systems. [41][42][43] Thus, the emerging scenario is that IFN-␣ may have some unique properties of acting as tumor suppressor gene and T cell adjuvant. With specific regard to our study, it is of interest to mention that recent reports have shown that CTLs which specifically recognize a wild-type p53 epitope efficiently lysed human breast carcinoma and melanoma cells which accumulated the p53 protein, 44 and significantly reduced the growth of human tumor xenografts in SCID mice.…”

Section: Discussionmentioning

confidence: 99%

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

et al. 2000

View full text Add to dashboard Cite

In this study, we describe the effects produced by the retroviral transduction of human type I consensus IFN (CIFN) coding sequence into the 8863 and 1B6 human melanoma cell lines, derived from a metastatic and a primary human melanoma, respectively. Melanoma cell lines producing approximately 10 3 IU/ml of IFN were obtained. Interestingly, cisplatin treatment of IFN-producing 8863 and 1B6 melanoma cells resulted in a three-to four-fold increase in the percentage of apoptotic cells with respect to similarly treated parental or control-transduced cell cultures. A similar effect, although less intense, was caused by cultivation of parental melanoma cells in the presence of exogenous CIFN. The increased susceptibility of the IFN-producing melanoma cell lines to cisplatin-induced apoptosis was associated with an IFN-dependent accumulation of p53, which also correlated with a decrease in Bcl-2 expression. Addition of exogenous CIFN to parental melanoma cells resulted in similar although weaker modulations of p53 and Bcl-2 expression. Cisplatin administration to nude mice bearing 3-day-old IFN-producing 8863 tumors resulted in complete tumor regression, while only a partial tumor inhibition was observed upon cisplatin treatment of mice bearing parental or control-transduced 8863 tumors. Starting the cisplatin treatment 7 days

show abstract

Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells

Cited by 250 publications

References 62 publications

Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo

Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo

Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

Contact Info

Product

Resources

About